IndustryCompany release

Bavarian Nordic Q3 revenue flat at DKK 1,805m as Travel Health grows 22%

Bavarian Nordic A/S · Fri 13 Nov 2026

Bavarian Nordic held its upgraded 2026 guidance of about DKK 6.1bn in revenue and a roughly 32% EBITDA margin, with travel vaccines offsetting a flat quarter overall.

Bavarian Nordic reported third-quarter 2026 revenue of DKK 1,805 million, unchanged from the same period a year earlier. Growth in its travel vaccine business was the main positive in the quarter.

Travel Health revenue rose 22%, driven by the rabies vaccine RabAvert/Rabipur and the launch of the chikungunya vaccine Vimkunya. The Public Preparedness segment, which covers government-supplied vaccines, contributed DKK 606 million.

The company kept its upgraded full-year guidance, which points to revenue of about DKK 6,100 million and an EBITDA margin of around 32%.

Bavarian Nordic also noted that the European Commission approved its MVA-BN vaccine against mpox and smallpox in August for children aged 2 to under 12. Separately, it said its chief financial officer is planned to leave in April 2027.

What it means for your team

  • The August EU approval for children aged 2 to under 12 widens the age range for MVA-BN in Europe; teams should check how it affects national product information and vaccination programmes.
  • Vimkunya's contribution to Travel Health growth shows the product moving into commercial use, which is relevant for pharmacovigilance and post-marketing monitoring planning.
  • Unchanged guidance suggests the company expects no material shift in its supply and contract outlook for the rest of 2026, though the source gives no further detail.

Company's press release: Bavarian Nordic A/S ↗

Article written by VigiEye from the official source (Bavarian Nordic A/S). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →